Review article: consensus statements on therapeutic drug monitoring of anti‐tumour necrosis factor therapy in inflammatory bowel diseases
Alimentary Pharmacology & Therapeutics2017Vol. 46(11-12), pp. 1037–1053
Citations Over TimeTop 1% of 2017 papers
Nikola Mitrev, Niels Vande Casteele, Cynthia H. Seow, John M. Andrews, Susan J. Connor, Gregory Moore, Murray L. Barclay, Jakob Begun, Robert V. Bryant, Webber Chan, Crispin Corte, Simon Ghaly, Daniel A. Lemberg, Viraj C. Kariyawasam, Peter Lewindon, Joseph Martin, Réme Mountifield, Graham Radford‐Smith, Peter Slobodian, Miles Sparrow, Catherine Toong, Daniel R. van Langenberg, Mark G. Ward, Rupert W. Leong
Abstract
Consensus statements support the role of TDM in optimising anti-TNF agents to treat IBD, especially in situations of treatment failure.
Related Papers
- → Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries(2014)128 cited
- → The Experience with Biosimilars of Infliximab in Rheumatic Diseases(2018)7 cited
- → Budget Impact Analysis Of Biosimilar Infliximab For The Treatment Of Crohn's Disease In Six Central Eastern European Countries(2014)5 cited
- → P471 Efficacy and safety of switching from reference infliximab to biosimilar infliximab in patients with inflammatory bowel disease: first French experience(2017)4 cited
- → P.07.13 SAFETY AND EFFICACY OF INFLIXIMAB BIOSIMILAR SB2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE WHO UNDERWENT A SWITCH FROM INFLIXIMAB BIOSIMILAR CT-P13(2019)4 cited